BioCentury | Oct 25, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Patient sample and mouse studies suggest inhibiting miR-27a could help treat tuberculosis (TB). In peripheral blood mononuclear cells (PBMCs) from patients with active pulmonary TB, levels of miR-27a were higher than in PBMCs...
BioCentury | Aug 29, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma; liver cancer; pancreatic cancer; colorectal cancer Mouse studies suggest inhibiting CD144 degradation could help treat melanoma, liver, pancreatic and colorectal cancers. In mouse models of melanoma and hepatocellular carcinoma (HCC), a previously reported...
BioCentury | Oct 17, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury MicroRNA-27a (miR-27a); VE-cadherin (CD144; cadherin-5) Mouse studies suggesting blocking the interaction between miR-27a and VE-cadherin transcripts could help...
BioCentury | May 19, 2011
Distillery Therapeutics

Indication: Ophthalmic disease

...Ophthalmic disease Age-related macular degeneration (AMD) MicroRNA-23 (miR-23); miR-27 Mouse studies suggest inhibiting miR-23 or miR-27...
...treat AMD and other vascular diseases. In mice, subretinal injection of anti-miRNAs against miR-23 or miR-27...
Items per page:
1 - 4 of 4